Lyme Disease Vaccine Pushes Valneva To US Listing

Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.

Tick
Ticks carrying Borrelia bacteria cause Lyme disease • Source: Shutterstock

French vaccines company Valneva SE is planning to list on the NASDAQ to fund Phase III studies of the much-needed vaccine for Lyme disease.

The company had a dual listing on the Vienna Stock Exchange and the EuroNext Paris, a legacy from Valneva’s formation...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category